跳至主要内容
临床试验/NCT06168968
NCT06168968招募中不适用

Multidisciplinary Approach to Reduce Cardiovascular Health Disparities in the Baltimore RAcial Minority CommunitiEs (M-BRACE Trial)

LifeBridge Health1 个研究点 分布在 1 个国家目标入组 400 人开始时间: 2023年2月6日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
400
试验地点
1
主要终点
Differences in Platelet Fibrin Clot Formation (MA,mm)

研究概览

简要总结

The goal of this observational study is to investigate the potential differences in thrombogenicity between black and white patients admitted with atherothrombotic events including acute coronary syndrome, multi-vessel coronary disease, and ischemic stroke.

Participants will engage in laboratory testing and health outcome assessments.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients ≥18 years of age admitted with ACS, AIS, or multi-vessel CAD
  • Competent mental condition to provide informed consent and able to participate in follow-ups

排除标准

  • Pregnant women
  • Currently enrolled in an investigational drug or device trial
  • Undergoing treatment for neoplastic, autoimmune, or connective tissue disease
  • COVID-19 infection within 30 days of enrollment
  • Known history of hepatitis or HIV
  • Deemed unfit to participate according to the investigator
  • Known history of drug abuse
  • Known platelet count of <100,000/mm3
  • Hematocrit < 25%

结局指标

主要结局

Differences in Platelet Fibrin Clot Formation (MA,mm)

时间窗: Baseline

Differences in Platelet Fibrin Clot Formation (MA,mm) Between Black and White Patients

Differences in Speed of Clot Formation (R, min)

时间窗: Baseline

Differences in Speed of Clot Formation (R, min) Between Black and White Patients

次要结局

  • Major Adverse Cardiovascular Events Post Index Hospitalization(3 and 12 months post index hospitalization)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Paul A. Gurbel

Director of Cardiovascular Research

LifeBridge Health

研究点 (1)

Loading locations...

相似试验

Multidisciplinary Approach to Reduce Cardiovascular... | 临床试验